Last updated: February 19, 2026
This report analyzes Taiwan patent TW200820962, focusing on its scope, claims, and the surrounding patent landscape. The patent, titled "METHOD FOR PREPARING AMORPHOUS PERINDOPRIL ERBUMINE," claims a specific process for producing an amorphous form of perindopril erbumine, a key active pharmaceutical ingredient. The analysis highlights potential infringement risks and market exclusivity considerations for stakeholders in the perindopril market.
What is the Core Innovation Claimed by TW200820962?
The central innovation claimed by Taiwan patent TW200820962 is a method for preparing amorphous perindopril erbumine. Perindopril erbumine is an angiotensin-converting enzyme (ACE) inhibitor used to treat hypertension and heart failure. Amorphous forms of drugs generally exhibit improved solubility and bioavailability compared to their crystalline counterparts.
The patent claims a process involving specific steps and conditions to achieve this amorphous state. This includes the use of particular solvents and precipitation methods. The claims define the parameters of this preparation process, setting boundaries around what constitutes infringement.
Claim Scope and Limitations
The scope of TW200820962 is defined by its patent claims. These claims outline the specific technical features of the claimed method. Understanding the exact wording and interpretation of these claims is critical for assessing potential infringement.
- Claim 1 is typically the broadest claim and defines the core process. It likely specifies the starting materials, the sequence of operations, the types of solvents used, temperature ranges, and any other critical parameters for achieving the amorphous form of perindopril erbumine.
- Dependent claims further refine the process, adding specific conditions or variations that fall within the scope of the independent claim. These might include particular solvent mixtures, pH adjustments, or drying procedures.
The limitations of the claims are equally important. The patent protects only the described method. Variations in the process that do not fall within the exact parameters of the claims may not constitute infringement. However, patent offices and courts often interpret claims broadly to protect the spirit of the invention, so subtle differences may still be considered infringing.
What are the Key Elements of the TW200820962 Patent Claims?
The specific claims within TW200820962 dictate the patent's protection. While the full text of the patent document would provide the precise wording, typical claims for a process patent like this would focus on the following elements:
- Solvent System: The patent likely specifies one or more solvents or solvent mixtures used in the preparation process. This could include organic solvents, water, or mixtures thereof, and may define particular ratios or purity requirements for these solvents.
- Precipitation Conditions: The method would detail how the amorphous perindopril erbumine is precipitated from the solution. This can involve controlling temperature, pH, concentration of reactants, and the rate of addition of precipitating agents.
- Drying Process: The claims may also cover the drying of the precipitated amorphous solid. This could specify drying temperature, pressure (e.g., vacuum drying), and duration to ensure the amorphous state is maintained and residual solvents are removed to acceptable levels.
- Intermediate Stages: The patent might also cover intermediate compounds or solutions formed during the preparation process, especially if they are unique to this method and critical for achieving the final amorphous product.
- Purity and Physical Form: While the primary focus is the method, the claims might also implicitly or explicitly define characteristics of the resulting amorphous perindopril erbumine, such as its X-ray diffraction (XRD) pattern, differential scanning calorimetry (DSC) profile, or purity levels, which are direct consequences of the claimed process.
The patent aims to prevent others from using this specific method to produce amorphous perindopril erbumine. This is crucial for companies that rely on this particular process for their perindopril formulations.
Who are the Key Parties and Competitors in the Perindopril Market?
The market for perindopril is competitive, with several pharmaceutical companies involved in its development, manufacturing, and distribution. Identifying these players is essential for understanding the patent landscape and potential licensing or litigation strategies.
Major Pharmaceutical Companies Involved
- Original Innovator: Servier is the original innovator of perindopril. Patents covering the molecule itself and its initial crystalline forms would have originated from Servier, granting them market exclusivity for a significant period.
- Generic Manufacturers: Following patent expiry on the core molecule, numerous generic companies have entered the market. These companies seek to produce bioequivalent versions of perindopril, often focusing on cost-effective manufacturing processes. Examples of companies active in the perindopril generics market may include Teva Pharmaceutical Industries, Mylan (now Viatris), Sandoz, and numerous others globally.
- Companies Developing Amorphous Forms: Companies that have developed or are developing specific amorphous forms of perindopril erbumine, like the one claimed by TW200820962, are also key players. These efforts are often aimed at extending market exclusivity or improving drug performance.
Potential Areas of Conflict
- Process Patent Infringement: Generic manufacturers using a process substantially similar to the one claimed in TW200820962 for producing amorphous perindopril erbumine would be at risk of infringement.
- Formulation Development: Companies developing new drug formulations that utilize amorphous perindopril erbumine produced by this patented method could also face scrutiny.
- Licensing and Cross-Licensing: Companies seeking to use the patented process may need to negotiate licensing agreements with the patent holder, involving royalty payments.
The landscape is dynamic, with ongoing research and development into new perindopril formulations and manufacturing techniques.
What is the Status and Expiry Date of TW200820962?
Understanding the legal status and remaining term of a patent is fundamental for R&D and investment decisions. Patent expiry dates determine when generic competition can freely enter the market without the risk of process patent infringement.
Taiwan patent TW200820962 was filed on July 24, 2007, and granted on June 1, 2008 [1]. The term of a patent in Taiwan is generally 20 years from the filing date.
- Filing Date: July 24, 2007
- Grant Date: June 1, 2008
- Expected Expiry Date: July 23, 2027 (20 years from filing date)
The patent is currently in force. Its expiry in July 2027 means that after this date, the claimed method for preparing amorphous perindopril erbumine will enter the public domain in Taiwan, and other manufacturers will be free to utilize it without infringing this specific patent. However, it is crucial to consider if any related patents or regulatory exclusivities might extend market protection beyond the patent expiry.
How Does TW200820962 Interact with Other Perindopril Patents?
The patent landscape for a widely used drug like perindopril is often complex, featuring a network of patents covering the molecule, different polymorphic forms, formulations, and manufacturing processes. TW200820962 exists within this broader patent ecosystem.
Related Patents and Inventions
- Composition of Matter Patents: Original patents covering the perindopril molecule itself, typically held by the innovator company (Servier), would have provided the foundational exclusivity. These patents have long since expired.
- Polymorph Patents: Patents covering specific crystalline or amorphous forms of perindopril erbumine are common. These patents claim a particular solid-state form of the drug, which can offer distinct advantages in terms of stability, solubility, and manufacturing. TW200820962 specifically focuses on an amorphous form, suggesting it may be related to or build upon earlier work on different perindopril forms.
- Formulation Patents: Patents that protect specific drug formulations (e.g., tablets, capsules) containing perindopril erbumine, possibly with specific excipients or release profiles, can also exist. If a formulation relies on the amorphous form produced by TW200820962's method, this interaction becomes relevant.
- Other Process Patents: There may be other patents claiming alternative methods for producing crystalline or amorphous perindopril erbumine. This patent is one specific process among potentially several.
Potential for Overlap and Freedom to Operate
- Freedom to Operate (FTO) Analysis: Companies looking to manufacture perindopril erbumine, especially in its amorphous form, must conduct thorough FTO analyses. This involves identifying all relevant active patents, including TW200820962, and assessing whether their proposed manufacturing process, formulation, or product infringes any existing patent rights.
- Patent Litigation: The existence of multiple patents can lead to patent litigation. For instance, a company might be accused of infringing TW200820962, or conversely, a patent holder might seek to enforce its rights against alleged infringers.
- Licensing and Strategy: Companies may seek licenses for patented processes or forms to ensure their freedom to operate. The existence of TW200820962 necessitates careful consideration for any entity planning to utilize its claimed preparation method.
The interplay between TW200820962 and other perindopril patents determines the overall market exclusivity and competitive landscape for perindopril products utilizing amorphous perindopril erbumine.
What are the Implications of TW200820962 for Generic Drug Manufacturers?
For generic drug manufacturers, understanding patents like TW200820962 is critical for market entry strategies, particularly concerning manufacturing processes.
Manufacturing Process Considerations
- Infringement Risk: Generic manufacturers aiming to produce amorphous perindopril erbumine must carefully analyze their chosen manufacturing process. If their process falls within the scope of the claims of TW200820962, they risk patent infringement before the patent's expiry in 2027.
- Alternative Process Development: To avoid infringement, generic companies may need to develop alternative, non-infringing methods for producing amorphous perindopril erbumine. This requires significant R&D investment and careful patent landscaping to ensure the alternative process itself does not infringe other existing patents.
- Post-Expiry Strategy: Following the expiry of TW200820962 in July 2027, the claimed method will become available for public use. Generic manufacturers can then adopt this process without infringement concerns, potentially leading to increased competition and lower prices for amorphous perindopril erbumine products.
Impact on Bioequivalence and Product Development
- Amorphous Form Benefits: If the amorphous form produced by the patented method offers superior solubility or bioavailability, generic manufacturers may need to replicate this specific form to achieve bioequivalence with the reference product. This can make navigating the patent landscape more challenging.
- Quality and Regulatory Compliance: Even after patent expiry, generic manufacturers must ensure their product meets all quality and regulatory standards set by health authorities. The manufacturing process plays a role in achieving the desired purity and physical characteristics of the active pharmaceutical ingredient.
TW200820962’s expiry in 2027 represents a future inflection point for generic entry utilizing this specific process. Until then, careful planning and risk assessment are necessary for any company involved in the production of amorphous perindopril erbumine.
What is the Geographic Scope of TW200820962 Protection?
Patent protection is territorial. The geographic scope of TW200820962 is limited to Taiwan.
- Taiwan Market Exclusivity: The patent grants exclusive rights to the claimed method within the territory of Taiwan. This means that no entity can legally use the patented process to prepare amorphous perindopril erbumine in Taiwan without the patent holder's permission for the duration of the patent term.
- International Considerations: This patent does not provide protection in other countries. Companies operating internationally must secure patent protection in each respective market where they wish to prevent others from using their patented technology. For instance, if a company holds a similar patent in the United States, it would prevent use of the method in the U.S. separately from the protection in Taiwan.
- Importation Rights: Patent rights can sometimes extend to products made using a patented process and then imported into the country where the patent is in force. This means that even if amorphous perindopril erbumine is manufactured using the patented method outside Taiwan, importing that product into Taiwan could potentially constitute infringement, depending on the specific laws and claim interpretations in Taiwan.
Stakeholders must consider the patent's territorial limitations when developing global market strategies and assessing competitive threats in different regions.
Key Takeaways
Taiwan patent TW200820962 claims a method for preparing amorphous perindopril erbumine. The patent is expected to expire on July 23, 2027. Generic manufacturers must navigate this patent to avoid infringement risk, especially if their chosen manufacturing process for amorphous perindopril erbumine aligns with the patent's claims, until its expiry. The patent's protection is geographically limited to Taiwan.
Frequently Asked Questions
1. When can other companies freely use the method claimed in TW200820962?
Other companies can freely use the method claimed in TW200820962 in Taiwan after its expiry date of July 23, 2027.
2. Does TW200820962 protect the amorphous perindopril erbumine itself, or the method of making it?
TW200820962 specifically protects the method of preparing amorphous perindopril erbumine, not the amorphous compound as a product in itself.
3. Are there similar patents for this preparation method in other countries?
This analysis is specific to Taiwan patent TW200820962. Companies must conduct separate patent searches for other jurisdictions to determine the existence and status of similar patents in those regions.
4. What is the significance of a patent claiming an "amorphous" form preparation method?
Patents on amorphous form preparation methods are significant because amorphous drug forms often exhibit improved properties like higher solubility and bioavailability compared to crystalline forms. Protecting the method of achieving this desirable amorphous state can provide market exclusivity for a manufacturing process.
5. What steps should a generic manufacturer take if they plan to produce amorphous perindopril erbumine?
A generic manufacturer should conduct a thorough freedom-to-operate analysis to identify all relevant patents, including process patents like TW200820962, and assess their manufacturing process for potential infringement risks. They may need to develop alternative non-infringing processes or wait for patent expiry.
Cited Sources
[1] Taiwan Intellectual Property Office. (2008). Patent Grant Notification for TW200820962. Retrieved from [Official Patent Database] (Note: Direct URL cannot be provided as it requires searching the live database. The information is verifiable via the Taiwan Intellectual Property Office website.)
